Effect of ubiquitin expression on neuropathogenesis in a mouse model of familial amyotrophic lateral sclerosis

Neuropathology and Applied Neurobiology

Volumn 31, Issue 1, 2005, Pages 20-33

  Gilchrist, C A ^a,d   Gray, D A ^b   Stieber, A ^c   Gonatas, N K ^c   Kopito, Ron R ^a  

^a STANFORD UNIVERSITY   (United States)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Amyotrophic lateral sclerosis; Transgenic mouse; Ubiquitin

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; MUTANT PROTEIN; PROTEASOME; UBIQUITIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CELL PROTECTION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; FAMILIAL AMYOTROPHIC LATERAL SCLEROSIS; FAMILIAL DISEASE; GENE EXPRESSION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBONUCLEASE PROTECTION ASSAY; SPINAL CORD; SURVIVAL; SYMPTOMATOLOGY; TRANSGENE; TRANSGENIC MOUSE; UBIQUITIN PROTEASOME SYSTEM;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; IMMUNOHISTOCHEMISTRY; INCLUSION BODIES; MALE; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; MOTOR ACTIVITY; MUTATION; NEURONS; SPINAL CORD; SUPEROXIDE DISMUTASE; TRANSGENES; UBIQUITIN;

EID: 13544275023     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2004.00604.x     Document Type: Article

References (68)

1. Siddique T. Molecular genetics of familial amyotrophic lateral sclerosis. Adv Neurol 1991; 56: 227-31
2. Emery AE, Holloway S. Familial motor neuron diseases. Adv Neurol 1982; 36; 139-47
3. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Bergh R, Hung W-Y, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitx HR, Brown RH. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62
4. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, Getzoff ED, Hu P, Herzfeldt B, Roos RP, Warner C, Deng G, Soriano E, Smyth C, Parge HE, Ahmed A, Roses AD, Hallewell RA, Pericak-Vance MA, Siddique T. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science 1993; 261: 1047-51
5. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, Chen W, Zhai P, Sufit RL, Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-5
6. Mourelatos Z, Gonatas NK, Stieber A, Gurney ME, Dal Canto MC. The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease. Proc Natl Acad Sci USA 1996; 93: 5472-7
7. Gonatas NK. Rous-Whipple Award Lecture. Contributions to the physiology and pathology of the Golgi apparatus. Am J Pathol 1994; 145: 751-61
8. Tu PH, Gurney ME, Julien JP, Lee VM, Trojanowski JQ. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab Invest 1997; 76: 441-56
9. Siddique T, Nijhawan D, Hentati A. Molecular genetic basis of familial ALS. Neurology 1996; 47: S27-34; discussion S34-5.
10. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH Jr, Scott RW, Snider WD. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13: 43-7
11. Julien JP. Amyotrophic lateral sclerosis unfolding the toxicity of the misfolded. Cell 2001; 104: 581-91
12. Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, Lee VM. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA 1996; 93: 3155-60
13. Stieber A, Gonatas JO, Gonatas NK. Aggregation of ubiquitin and a mutant ALS-linked SOD1 protein correlate with disease progression and fragmentation of the Golgi apparatus. J Neurol Sci 2000; 173: 53-62
14. Kato S, Horiuchi S, Liu J, Cleveland DW, Shibata N, Nakashima K, Nagai R, Hirano A, Takikawa M, Kato M, Nakano I, Ohama E. Advanced glycation endproduct-modified superoxide dismutase-1 (SOD1)-positive inclusions are common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutations and transgenic mice expressing human SOD1 with a G85R mutation. Acta Neuropathol (Berl) 2000; 100: 490-505
15. Hoffman EK, Wilcox HM, Scott RW, Siman R. Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J Neurol Sci 1996; 139: 15-20
16. Nakano R, Inuzuka T, Kikugawa K, Takahashi H, Sakimura K, Fujii J, Taniguchi N, Tsuji S. Instability of mutant Cu/Zn superoxide dismutase (Ala4Thr) associated with familial amyotrophic lateral sclerosis. Neurosci Lett 1996; 211: 129-31
17. Johnston JA, Dalton MJ, Gurney ME, Kopito RR. Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000; 97: 12571-6
18. Urushitani M, Kurisu J, Tsukita K, Takahashi R. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem 2002; 83: 1030-42
19. Niwa J, Ishigaki S, Hishikawa N, Yamamoto M, Doyu M, Murata S, Tanaka K, Taniguchi N, Sobue G. Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J Biol Chem 2002; 277: 36793-8
20. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000; 22: 442-51
21. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-79
22. Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME. Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci 1998; 21: 516-20
23. Lowe J, Mayer RJ. Ubiquitin, cell stress and diseases of the nervous system. Neuropathol Appl Neurobiol 1990; 16: 281-91
24. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001; 292: 1552-5
25. Jana NR, Zemskov EA, Wang G, Nukina N. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 2001; 10: 1049-59
26. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J Biol Chem 2003; 278: 11753-9
27. Mizuno Y, Hattori N, Mod H, Suzuki T, Tanaka K. Parkin and Parkinson's disease. Curr Opin Neurol 2001; 14: 477-82
28. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451-2
29. Levecque C, Destee A, Mouroux V, Becquet E, Defebvre L, Amouyel P, Chartier-Harlin MC. No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J Neural Transm 2001; 108: 979-84
30. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, Toda T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol 2002; 51: 133-6
31. Satoh J, Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J Neurol Sci 2001; 189: 113-7
32. Wang J, Zhao CY, Si YM, Liu ZL, Chen B, YuL. ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov Disord 2002; 17: 767-71
33. Nishikawa K, Li H, Kawamura R, Osaka H, Wang YL, Kara Y, Hirokawa T, Manage Y, Amano T, Noda M, Aoki S, Wada K. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 2003; 304: 176-83
34. Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 1999; 53: 1858-60
35. Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, Harada T, Ichihara N, Wakana S, Kikuchi T, Wada K. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999; 23: 47-51
36. Wilson SM, Bhattacharyya B, Rachel RA, Coppola V, Tessarollo L, Householder DB, Fletcher CF, Miller RJ, Copeland NG, Jenkins NA. Synaptic defects in ataxia mice result from a mutation in Usp14. encoding a ubiquitin-specific protease. Nat Genet 2002; 32: 420-5
37. He L, Lu XY, Jolly AF, Eldridge AG, Watson SJ, Jackson PK, Barsh GS, Gunn TM. Spongiform degeneration in mahoganoid mutant mice. Science 2003; 299: 710-2
38. Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet 1996; 30: 405-39
39. Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK, Varshavsky A. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 1989; 243: 1576-83
40. Johnson ES, Ma PC, Ota JM, Varshavsky A. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 1995; 270: 17442-56
41. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 1999; 96: 635-44
42. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. Embo J 2000; 19: 94-102
43. Piotrowski J, Beal R, Hoffman L, Wilkinson KD, Cohen RE, Pickart CM. Inhibition of the 26 S proteasome by polyubiquitin chains synthesized to have defined lengths. J Biol Chem 1997; 272: 23712-21
44. Tsirigotis M, Thurig S, Dube M, Vanderhyden BC, Zhang M, Gray DA. Analysis of ubiquitination in vivo using a transgenic mouse model. Biotechniques 2001; 31: 120-6,128,130
45. Zhang M, Thurig S, Tsirigotis M, Wong PK, Reuhl KR, Gray DA. Effects of mutant ubiquitin on ts1 retrovirus-mediated neuropathology. J Virol 2003; 77: 7193-201
46. Rasoulpour RJ, Schoenfeld HA, Gray DA, Boekelheide K. Expression of a K48R mutant ubiquitin protects mouse testis from cryptorchid injury and aging. Am J Pathol 2003;163:2595-603
47. Tsirigotis M, Zhang M, Chiu RK, Wouters BG, Gray DA. Sensitivity of mammalian cells expressing mutant ubiquitin to protein-damaging agents. J Biol Chem 2001; 276: 46073-8
48. Pinheiro JV, Bates DM. Mixed Effects Models in S and S-PLUS, 1st edn. New York: Springer-Verlag 2000; 528
49. Croul S, Mezitis SG, Stieber A, Chen YJ, Gonatas JO, Goud B, Gonatas NK. Immunocytochemical visualization of the Golgi apparatus in several species, including human, and tissues with an antiserum against MG-160, a sialoglyco-protein of rat Golgi apparatus. J Histochem Cytochem 1990; 38: 957-63
50. Gonatas JO, Mezitis SG, Stieber A, Fleischer B, Gonatas NK. MG-160. A novel sialoglycoprotein of the medial cisternae of the Golgi apparatus published erratum appears in J Biol Chem 1989 March 5; 264 (7):4264. J Biol Chem 1989; 264: 646-53
51. Gonatas JO, Mezitis SG, Stieber A, Fleischer B, Gonatas NK. MG-160. A novel sialoglycoprotein of the medial cisternae of the Golgi apparatus published erratum appears in J Biol Chem 1989 March 5; 264 (7):4264. J Biol Chem 1989; 264: 646-53
52. Gonatas JO, Mourelatos Z, Stieber A, Lane WS, Brosius J, Gonatas NK. MG-160, a membrane sialoglycoprotein of the medial cisternae of the rat Golgi apparatus, binds basic fibroblast growth factor and exhibits a high level of sequence identity to a chicken fibroblast growth factor receptor. J Cell Sci 1995; 108 (Pt 2): 457-67
53. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23: 249-56
54. Levine JB, Kong J, Nadler M, Xu Z. Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS). Glia 1999; 28: 215-24
55. Finley D, Sadis S, Monia BP, Boucher P, Ecker DJ, Crooke ST, Chau V. Inhibition of proteolysis and cell cycle progression in a multiubiquitination- deficient yeast mutant. Mol Cell Biol 1994: 14: 5501-9
56. Bruening W, Roy J, Giasson B, Figlewicz DA, Mushynski WE, Durham HD. Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis. J Neurochem 1999; 72: 693-9
57. Chai Y, Koppenhafer SL, Bonini NM, Paulson HL. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J Neurosci 1999; 19: 10338-47
58. Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999; 23: 425-8
59. Gray DA. Damage control - a possible non-proteolytic role for ubiquitin in limiting neurodegeneration. Neuropathol Appl Neurobiol 2001; 27: 89-94
60. Barneoud P, Curet O. Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. Exp Neurol 1999; 155: 243-51
61. Feeney SJ, McKelvie PA, Austin L, Jean-Francois MJ, Kapsa R, Tombs SM, Byrne E. Presymptomatic motor neuron loss and reactive astrocytosis in the SOD1 mouse model of amyotrophic lateral sclerosis. Muscle Nerve 2001; 24: 1510-9
62. Fujita Y, Okamoto K, Sakurai A, Gonatas NK, Hirano A. Fragmentation of the Golgi apparatus of the anterior horn cells in patients with familial amyotrophic lateral sclerosis with SOD1 mutations and posterior column involvement. J Neurol Sci 2000; 174: 137-40
63. Gonatas NK, Stieber A, Mourelatos Z, Chen Y, Gonatas JO, Appel SH, Hays AP, Hickey WF, Hauw JJ. Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis. Am J Pathol 1992; 140: 731-7
64. Mancini M, Machamer CE, Roy S, Nicholson DW, Thornberry NA, Casciola-Rosen LA, Rosen A. Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. J Cell Biol 2000; 149: 603-12
65. Murakami T, Nagano I, Hayashi T, Manabe Y, Shoji M, Setoguchi Y, Abe K. Impaired retrograde axonal transport of adenovirus-mediated E. coli LacZ gene in the mice carrying mutant SOD1 gene. Neurosci Lett 2001; 308: 149-52
66. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 1999; 2: 50-6
67. Warita H, Abe K, Setoguchi Y, Itoyama Y. Expression of adenovirus-mediated E. coli lacZ gene in skeletal muscles and spinal motor neurons of transgenic mice with a mutant superoxide dismutase gene. Neurosci Lett 1998; 246: 153-6
68. Borchelt DR, Wong PC, Becher MW, Pardo CA, Lee MK, Xu ZS, Thinakaran G, Jenkins NA, Copeland NG, Sisodia SS, Cleveland DW, Price DL, Hoffman PN. Axonal transport of mutant superoxide dismutase 1 and focal axonal abnormalities in the proximal axons of transgenic mice. Neurobiol Dis 1998; 5: 27-35